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Hyponatremia in patients with 
systemic lupus erythematosus
Jae Il Shin1,2,*, Se Jin Park3,*, Chang-Hee Suh4,*, Geum Hwa Lee1, Min Woo Hur1, Song Yi Han1, 
Dong Soo Kim1 & Ji Hong Kim1,5
The aim of this study was to determine whether decreased serum sodium concentration could 
be associated with the disease activity in SLE. We retrospectively analyzed the data of the two 
independent cohorts of children and adults with SLE in two centers. Hyponatremia was associated with 
serum chloride (p = 0.004), albumin (p = 0.002) and SLE disease activity index (SLEDAI) (p = 0.026) in 
children with SLE. Serum sodium levels were correlated negatively with ESR (p =0.001) and positively 
with serum albumin levels (p < 0.0001) and C3 (p = 0.008) in children with SLE and those levels were 
correlated negatively with serum interleukin-6 levels (p = 0.003) in adults with SLE. Independent risk 
factors for the development of hyponatremia were the decreased serum C3 levels (OR 1.069, p = 0.031), 
the decreased serum chloride levels (OR 2.054, p = 0.006) and increased erythrocyte sedimentation 
rate (ESR) (OR 1.066, p = 0.03) in children with SLE and increased C-reactive protein (CRP) (OR 1.480, 
p = 0.023) in combined cohorts with SLE by multiple logistic regression analyses. Our study firstly 
showed that hyponatremia could reflect a disease activity and severe inflammation of SLE.
Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease with a highly variable clini-
cal course1,2. During the course of the disease, decreased serum levels of C3, C4 and high anti-double stranded 
(anti-ds) DNA antibody titers are reported to be associated with the disease activity and poor survival3.
Hyponatremia is known to be one of the most common electrolyte abnormalities and can cause seizures, brain 
edema, encephalopathy, and even death4,5. Hyponatremia has been reported to be poor clinical outcome such as 
mortality in general population, dialyzed patients and those with heart failure, cirrhosis and sepsis6–8. However, 
the incidence and clinical significance of hyponatremia has not been studied in rheumatic diseases including 
SLE and only some case reports of hyponatremia have been reported in SLE9,10. Also, there has been no report 
describing the relationship between the degree of hyponatremia and the disease activity in both childhood and 
adulthood SLE.
Therefore, the aim of this study was to evaluate the clinical and laboratory characteristics related to disease 
activity in children and adults with SLE and determine whether decreased serum sodium concentration could be 
associated with the disease activity in SLE.
Results
A cohort of children and adolescents with SLE.  Laboratory characteristics of the patients with (Group I, 
n = 11) and without hyponatremia (Group II, n = 63) are shown in Table 1. There were no significant differ-
ences in white blood cell (WBC) counts, hemoglobin, hematocrit, platelet counts, erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP), serum potassium, total carbon dioxide (tCO2), blood urea nitrogen (BUN), 
creatinine, total protein, cholesterol, uric acid, alanine aminotransferase (ALT) and total bilirubin between the 
two groups (p > 0.05). However, serum chloride (p = 0.004), albumin (p = 0.002), aspartate aminotransferase 
(AST) levels (p = 0.004) and SLE disease activity index (SLEDAI) (p = 0.026) were significantly higher and serum 
calcium levels (p = 0.004) were significantly lower in SLE patients with hyponatremia than those without.
The positivity of antinuclear antibody (ANA), anti-ds DNA antibody and other autoantibodies, and the inci-
dence of proteinuria did not differ between the two groups. However, serum C3 levels which reflect the disease 
activity were significantly lower in SLE patients with hyponatremia than those without (p = 0.004) (Table 2).
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Independent risk factors for the development of hyponatremia were the decreased serum C3 levels (OR 1.069, 
p = 0.031), the decreased serum chloride levels (OR 2.054, p = 0.006) and increased erythrocyte sedimentation 
rate (ESR) (OR 1.066, p = 0.03) in children with SLE by multiple logistic regression analysis (Table 3).
The values of area under the curves (AUC) for the prediction of hyponatremia in children with SLE were 0.749 
(95% CI 0.589–0.908, p = 0.026) for high SLEDAI, 0.779 (95% CI 0.613–0.946, p = 0.012) for high ESR levels, 
0.775 (95% CI 0.599–0.951, p = 0.013) for high AST levels, 0.758 (95% CI 0.563–0.953, p = 0.021) for decreased 
serum C3 levels and 0.778 (95% CI 0.650–0.906, p = 0.013) for decreased serum albumin levels.
Group I with 
hyponatremia (n = 11)
Group II without 
hyponatremia (n = 63) P value
WBC (/μ L) 8,456 ± 6,081 6,831 ± 3,641 0.933
ESR (mm/hr) 48.8 ± 31.9 29.9 ± 23.3 0.073
CRP (mg/dL) 3.6 ± 6.8 0.6 ± 0.8 0.478
Hb (g/dL) 10.8 ±  ± 2.2 11.2 ± 2.1 0.140
Hct (%) 31.5 ± 6.6 32.7 ± 6.5 0.138
PLT (/μ L) 226,364 ± 145,007 247,694 ± 107,885 0.418
Na (mmol/L) 131.4 ± 4.1 139.1 ± 2.3 < 0.001
K (mmol/L) 3.7 ± 0.6 4.1 ± 0.5 0.105
Cl (mmol/L) 98.4 ± 9.3 104.5 ± 3.3 0.004
tCO2 (mmol/L) 22.7 ± 5.1 23.0 ± 3.1 0.994
BUN (mg/dL) 12.8 ± 4.5 11.7 ± 4.9 0.456
Creatinine (mg/dL) 0.6 ± 0.1 0.6 ± 0.2 0.994
AST (IU/L) 73 ± 70 33 ± 38 0.004
ALT (IU/L) 58 ± 79 24 ± 22 0.074
Total protein (g/dL) 6.7 ± 1.3 6.8 ± 0.9 0.330
Albumin (g/dL) 3.3 ± 0.4 4.0 ± 0.8 0.002
Uric acid (mg/dL) 5.0 ± 1.6 4.8 ± 1.2 0.835
Cholesterol (mg/dL) 150 ± 49 177 ± 83 0.176
Calcium (mg/dL) 8.0 ± 1.1 9.0 ± 0.8 0.004
Phosphorus (mg/dL) 3.3 ± 1.4 4.1 ± 1.0 0.124
Total bilirubin (mg/dL) 0.8 ± 0.8 0.6 ± 0.8 0.184
SLEDAI (score) 6.9 ± 6.1 3.1 ± 3.4 0.026
Table 1.  General laboratory findings of children with lupus with or without hyponatremia. WBC white 
blood cell, ESR erythrocyte sedimentation rate, CRP C-reactive protein, Hb hemoglobin, Hct hematocrit, PLT 
platelet, Na Sodium, K potassium, Cl Chloride, tCO2 total carbon dioxide, BUN blood urea nitrogen, AST 
aspartate aminotransferase, ALT alanine aminotransferase, SLEDAI Systemic lupus erythematosus disease 
activity index.
Group I (n = 11) Group II (n = 63) P value
C3 (mg/dL) 38.4 ± 26.1 67.3 ± 28.6 0.004
C4 (mg/dL) 8.2 ± 6.5 13.8 ± 8.8 0.028
ANA 10(90.9%) 51(81.0%) 0.676
anti ds-DNA 8(72.7%) 29(46.0%) 0.190
Proteinuria 3(27.3%) 14(22.2%) 0.707
Anti-Sm 1/2(50%) 7/16(43.8%) 1.000
Anti-Ro 3/7(42.9%) 9/30(30%) 0.659
Anti-La 0/7(0%) 4/29(13.8%) 0.566
Anti-RNP 1/1(100%) 5/8(62.5%) 1.000
Anti-platelet antibody 2/4(50%) 2/4(50%) –
LA 1/1(100%) 2/3(66.7%) 1.000
ACL 1/2(50%) 1/8(12.5%) 0.378
Anti-β 2 GPI 0/5(0%) 0/5(0%) –
Table 2.  Immunologic laboratory findings and proteinuria of children with lupus with or without 
hyponatremia. C3 complement component 3, ANA antinuclear antibody, Anti-ds DNA Anti-double-
stranded DNA (Deoxyribonucleic acid), Anti-RNP Anti-Ribonucleoprotein, LA Lupus anticoagulant, ACL 
anticardiolipin antibodies, Anti-β2 GPI Anti-β 2-glycoprotein I.
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In addition, serum sodium levels were correlated negatively with ESR (r = − 0.399, p = 0.001) and serum AST 
levels (r = − 0.334, p = 0.004), but positively with C3 (r = 0.304, p = 0.008), serum chloride (r = 0.372, p = 0.001), 
serum calcium (r = 0.549, p < 0.0001) and serum albumin levels (r = 0.479, p < 0.0001) (Table 4).
Furthermore, changes in serum sodium levels (Na levels at the follow-up state– Na levels at the initial state, 
Δ Na) correlated positively with changes in serum C3 (Δ C3) (r = 0.476, p = 0.003), serum C4 (Δ C4) (r = 0.357, 
p = 0.03), hemoglobin (Δ Hb) (r = 0.340, p = 0.039), hematocrit (Δ Hct) (r = 0.425, p = 0.009), chloride (Δ chlo-
ride) (r = 0.466, p = 0.004), calcium (Δ calcium) (r = 0.385, p = 0.019), phosphorus (Δ phosphorus) (r = 0.391, 
p = 0.017) and albumin levels (Δ albumin) (r = 0.481, p = 0.003). However, Δ Na were not correlated with 
changes in SLEDAI (Δ SLEDAI) (r = − 0.191, p = 0.313) (Table 5).
A cohort of adolescents and adults with SLE.  Laboratory characteristics of the patients with (n = 7) 
and without hyponatremia (n = 77) are shown in Supplementary Table S1. There were no significant differences 
in WBC counts, SLEDAI, interleukin (IL)-6, IL-2, the dose of steroids and urine specific gravity between the two 
groups (p > 0.05). CRP levels were higher in SLE patients with hyponatremia than those without with a border-
line significance (p = 0.077).
Serum sodium levels were correlated negatively with serum IL-6 levels (r = − 0.317, p = 0.003), while those 
did not correlate to serum IL-2 levels (p = 0.389). Serum IL-6 levels were also positively correlated with SLEDAI 
(r = 0.386, p = 0.032) (Table 6). The significant correlations between serum sodium and IL-6 levels were more 
prominent in SLE patients who were not treated with steroids (r = − 0.424, p = 0.017) than those who were 
treated with steroids (r = − 0.247, p = 0.075). In SLE patients who were not treated with steroids, serum sodium 
Odds ratio 95% CI P value
ESR (mm/hr) 1.066 1.006–1.130 0.03
Chloride (mmol/L) 2.054 1.229–3.433 0.006
C3 (mg/dL) 1.069 1.006–1.136 0.031
Table 3.  Multiple logistic regression analysis of laboratory parameters associated with the development of 
lupus-associated hyponatremia in children with lupus. ESR erythrocyte sedimentation rate, C3 complement 
component 3.
Na C3 ESR Cl Ca Alb AST SLEDAI
Na . 0.008 0.001(− ) 0.001 < 0.0001 < 0.0001 0.004(− ) 0.060
C3 0.008 . 0.003(− ) 0.025 < 0.0001 < 0.0001 0.001(− ) < 0.0001(− )
ESR 0.001(− ) 0.003(− ) . 0.545 0.004(− ) 0.001(− ) 0.107 0.015
Cl 0.001 0.025 0.545 . 0.375 0.157 0.034(− ) 0.612
Ca < 0.0001 < 0.0001 0.004(− ) 0.375 . < 0.0001 0.004 (− ) 0.058
Alb < 0.0001 < 0.0001 0.001(− ) 0.157 < 0.0001 . < 0.0001(− ) 0.016(− )
AST 0.004(-) 0.001(− ) 0.107 0.034(− ) 0.004(− ) < 0.0001(− ) . 0.002
SLE DAI 0.060 < 0.0001(− ) 0.015 0.612 0.058 0.016(− ) 0.002 .
Table 4.  Correlations among key laboratory findings in children with lupus. Na Sodium, C3 complement 
component 3, ESR erythrocyte sedimentation rate, Cl Chloride, Ca Calcium, Alb Albumin, AST aspartate 
aminotransferase, SLEDAI Systemic lupus erythematosus disease activity index, (− ): negative correlation.
ΔNa ΔC3 ΔC4 ΔHb ΔHct ΔCl ΔCa ΔP ΔAlb ΔSLEDAI
Δ Na . 0.003 0.030 0.039 0.009 0.004 0.019 0.017 0.003 0.313
Δ C3 0.003 . < 0.0001 < 0.0001 0.003 0.706 0.001 0.025 < 0.0001 0.052(− )
Δ C4 0.030 < 0.0001 . 0.001 0.013 0.840 0.060 0.048 0.002 0.044(− )
Δ Hb 0.039 < 0.0001 0.001 . < 0.0001 0.739 0.028 0.197 0.037 0.006(− )
Δ Hct 0.009 0.003 0.013 < 0.0001 . 0.473 0.040 0.176 0.058 0.008(− )
Δ Cl 0.004 0.706 0.840 0.739 0.473 . 0.564 0.949 0.418 0.208
Δ Ca 0.019 0.001 0.060 0.028 0.040 0.564 . 0.001 < 0.0001 0.391
Δ P 0.017 0.025 0.048 0.197 0.176 0.949 0.001 . 0.013 0.712
Δ Alb 0.003 < 0.0001 0.002 0.037 0.058 0.418 < 0.0001 0.013 . 0.170
Δ SLEDAI 0.313 0.052(− ) 0.044(− ) 0.006(− ) 0.008(− ) 0.208 0.391 0.712 0.170 .
Table 5.  Correlations among changes in laboratory findings in children with lupus. Na Sodium, C3 
complement component 3, C4 complement component 4, Hb Hemoglobin, Hct Hematocrit, Cl Chloride, Ca 
Calcium, P Phosphorus, Alb Albumin, SLEDAI Systemic lupus erythematosus disease activity index, (− ): 
negative correlation.
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levels were correlated negatively with urine specific gravity which reflect the effect of ADH with a borderline 
significance (r = − 0.326, p = 0.073) (Supplementary Tables S2–S3).
Two combined cohorts of children and adults with SLE. In univariate analyses, there were no signif-
icant differences in WBC counts and SLEDAI between the two groups (p > 0.05) and ESR (p = 0.053) and CRP 
levels (p = 0.053) were higher in SLE patients with hyponatremia (n = 18) than those without (n = 140) with 
borderline significances (Supplementary Table S4).
Multiple logistic regression analysis showed that increased CRP level (OR 1.480, p = 0.023) was an inde-
pendent risk factor for the development of hyponatremia in combined cohorts of children and adults with SLE 
(Supplementary Table S5). In addition, serum sodium levels were correlated negatively with CRP (r = − 0.368, 
p < 0.0001) and ESR levels (r = − 0.189, p = 0.023) (Supplementary Table S6).
Receiver operating characteristic (ROC) curves.  To establish the predictive value of the parameters for 
predicting hyponatremia in patients with lupus, ROC curves were plotted for SLEDAI, ESR, AST, serum C3 and 
albumin levels.
AUC values from ROC curve analyses for SLEDAI, ESR, AST, serum C3 and albumin levels were 0.743 
(P = 0.029), 0.768 (P = 0.016), 0.770 (P = 0.015), 0.746 (P = 0.027) and 0.777 (P = 0.013), respectively 
(Supplementary Table S7 and Figure S1).
Discussion
The main goal of this study was to investigate the significance of hyponatremia in children and adults with SLE 
and determine whether hyponatremia is associated with disease activity. Our study firstly demonstrated the asso-
ciation of hyponatremia with the decreased C3 and increased ESR levels and SLEDAI which reflect disease activ-
ity of SLE in a cohort of children with SLE and serum sodium levels were correlated negatively with serum IL-6 
levels in an independent cohort of adults with SLE, which have not been investigated in both adults and children 
over the past decade.
Hyponatremia can occur in patients with SLE by various causes such as renal disease, acute kidney injury, and 
medication use, but only very few case reports were found in literatures on hyponatremia in SLE9,10. Although 
the exact mechanism of hyponatremia in SLE flare patients is not established yet, we speculate that inflammation 
can be one of the mechanisms in the pathogenesis of hyponatremia in SLE patients. In a cohort of children with 
SLE, we found that decreased serum chloride levels were independent risk factors for the development of hypon-
atremia in children with SLE. Urinary loss of sodium chloride could cause hyponatremia and hypochloremia and 
it can be caused by renal tubular damage or increased renal sodium loss by a reduction in renal tubular sodium 
absorption in inflammatory conditions11–20. However, we excluded the SLE patients with evident renal failure, 
because tubular injury can cause natriuresis and hyponatremia which obscure the relationship between lupus 
activity and serum sodium levels. Therefore, serum creatinine levels and the degree of proteinuria did not differ 
in SLE patients with hyponatremia than those without.
Eisenhut pointed out that inflammatory mediators such as IL-1 and tumor necrosis factor (TNF)-α have been 
reported to reduce sodium transport in epithelial cells by a reduction in the expression and function of the apical 
epithelial sodium channel (ENaC) and/or the sodium potassium ATPase (Na/K ATPase) at the basolateral mem-
brane11,12. It was also demonstrated that IL-1 could induce natriuresis in the rat model13. Using cultures of inner 
medullary, cortical collecting duct and proximal tubular renal cells in vitro, the potential mechanisms were found 
to involve a reduction in the Na/K ATPase function mediated by prostaglandin E214–18 and by increasing tissue 
levels of nitric oxide, which is a potent suppressor of the epithelial Na/K ATPase by the intracellular messenger 
cGMP and through protein kinase G modification19,20. An activation of the autoimmune system in SLE can cause 
CD8 + T-cells and macrophages to produce pro-inflammatory cytokines and chemokines, such as interleukin 
(IL)-1, IL-6, IL-8 and TNF-α 21–24.
Because the degree of proteinuria did not differ in SLE children with hyponatremia than those without and 
our children with SLE did not have nephrotic syndrome or severe renal disease, hypoalbuminemia might occur 
by severe inflammation through a disease activity of SLE. Hypoalbuminemia has been regarded as an important 
Na WBC ESR CRP SLE DA1 IL-6 IL-2 Steroid SG
Na . 0.373 0.070 0.446 0.716 0.003(− ) 0.389 0.710 0.486
WBC 0.373 . 0.623 0.232 0.256 0.399 0.487 0.005 0.865
ESR 0.070 0.623 . 0.026 0.438 0.010 0.587 0.915 0.293
CRP 0.446 0.232 0.026 . 0.092 0.004 1.000 0.424 0.012(− )
SLEDAI 0.716 0.256 0.438 0.092 . 0.051 0.321 0.305 0.801
IL-6 0.003(− ) 0.399 0.010 0.004 0.051 . 0.339 0.918 0.798
IL-2 0.389 0.487 0.587 1.000 0.321 0.339 . 0.979 0.032
Steroid 0.710 0.005 0.915 0.424 0.305 0.918 0.979 . 0.644
SG 0.486 0.865 0.293 0.012(− ) 0.801 0.798 0.032 0.644
Table 6.  Correlations among key laboratory findings in adults with lupus. Na Sodium, WBC white blood 
cell, ESR erythrocyte sedimentation rate, CRP C-reactive protein, SLEDAI Systemic lupus erythematosus 
disease activity index, IL-6 Interleukin-6, IL-2 Interleukin-2, SG urine specific gravity, (− ): negative correlation.
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cause of appreciable hypovolemic hyponatremia25. Also, it was thought that decreased serum calcium levels could 
be caused by hypoalbuminemia in our children’s cohort.
We found that hyponatremia was associated with increased ESR, CRP, and SLEDAI and decreased serum 
albumin and C3 levels by various statistical methods (univariate, multivariate and correlation analyses) in our 
cohorts of SLE, suggesting that hyponatremia in SLE is closely related to more severe inflammation. Although not 
studied yet in SLE, there have been some evidences and our hypothetical background showing that IL-1β or IL-6 
might increase antidiuretic hormone (ADH) secretion, leading to hyponatremia26–31. Mastorakos et al. reported 
that plasma ADH levels were increased after injection of IL-6 in cancer patients, suggesting that IL-6 activated 
the magnocellular ADH-secreting neurons, which could be involved in the development of SIADH26. Ohta et al. 
performed animal experiments and intravenous administrations of IL-1β increased ADH27. Because IL-6 and 
IL-1β are all important cytokines in the pathogenesis of SLE both in animal models and human SLE21–24, there is a 
possibility that increased these cytokines could be implicated in the pathogenesis of hyponatremia in the patients 
with SLE. To validate this hypothesis, we analyzed the relationship between serum sodium and IL-6 levels in an 
independent cohort of adults with SLE and found that serum sodium levels were correlated negatively with serum 
IL-6 levels (r = − 0.317, p = 0.003), which was more prominent in SLE patients who were not treated with steroids 
(r = − 0.424, p = 0.017). In SLE patients who were not treated with steroids, serum sodium levels were correlated 
negatively with urine specific gravity which reflect the effect of ADH with a borderline significance (r = − 0.326, 
p = 0.073).
Our study has some limitations, such as small sample size due to the rarity of lupus in Korea, retrospec-
tive study design. Nevertheless, the current data are noteworthy because we firstly showed that hyponatremia 
reflected disease activity of SLE in two independent cohorts of children and adults with SLE. Therefore, clinicians 
should recognize this electrolyte disturbance in SLE and pediatricians should pay more attention to the risk 
for exacerbating hyponatremia by administering a hypotonic fluid in children. Further studies are necessary to 
evaluate the exact molecular mechanism of hyponatremia in SLE and to elucidate whether our findings are also 
relevant in a large cohort of SLE in the future.
Patients and Methods
A cohort of children and adolescents with SLE.  We retrospectively analyzed the data of 37 children 
(male:female = 4:33) who had been diagnosed with SLE in Severance Children’s Hospital for 20 years from the 
years 1991 to 2010. Laboratory examinations were collected two times at the stage of disease activity and at fol-
low-up after 22.2 ± 28.3 months (range 1–123 months) in all patients. We divided the patients into two groups: 
group I (n = 11 samples, hyponatremia) and group II (n = 63 samples, no hyponatremia).
Medical charts were reviewed for clinical characteristics, such as age at onset, gender, and laboratory data, 
including WBC counts, hemoglobin, hematocrit, platelet counts, ESR, CRP, serum sodium, potassium, chloride, 
tCO2, calcium, phosphorus, BUN, creatinine, total protein, albumin, cholesterol, uric acid, AST, ALT, total bili-
rubin, and urinalysis.
Serum sodium assay was evaluated by using ion selective electrodes measurement by an automated chem-
istry analyzer (Olympus AU-2700, Beckman coulter, Mishima, Japan). Complete blood counts including plate-
let counts were analyzed by the Advia 2120i automated analyzer (Siemens Healthcare Diagnostics, Deerfield, 
IL, USA). CRP levels were measured by the latex-enhanced turbidimetric assay method using a Hitachi 7600 P 
module (Hitachi, Tokyo, Japan). ESR levels were measured by the TEST 1 (Alifax, Padova, Veneto, Italy). Serum 
C3 and C4 levels were measured by the automated Roche Diagnostics analyzer (Hitachi Cobas C501, Roche 
Diagnostics GmbH, Mannheim, Germany). Antinuclear antibodies and anti-ds DNA antibodies were detected by 
immunofluorescence using Crithidia luciliae (Department of Laboratory Medicine, Severance Hospital, Seoul). 
Strict quality control procedures were adopted.
A cohort of adolescents and adults with SLE.  Among 166 SLE patients who were followed up at 
Ajou University Hospital and in whom IL-6 levels were measured23, 84 were included in the study (age: mean 
34.4 ± 12.1 years [range 16–69 years], male : female = 8:76) in whom serum sodium levels were available. 
Laboratory parameters of disease activity were recorded such as WBC counts, ESR, CRP, and urine specific gravity 
and SLEDAI was also calculated. Measurements of IL-2 and IL-6 in serum samples were performed by sand-
wich enzyme-linked immunosorbent assay (ELISA) using BD OptEIA sets (Pharmingen, San Diego, CA). All 
serum samples were measured in triplicate and diluted 1:1 in assay diluent for OptEIA ELISA sets. Briefly, after 
coating with primary anti-human IL-2 and IL-6 antibodies (Pharmingen) and blocking, 100 μ g of diluted serum 
was loaded, and biotinylated secondary anti-human IL-2 and IL-6 monoclonal antibodies (Pharmingen) were 
added, respectively. The wells were incubated with streptavidine horseradish peroxidase conjugate, and color-
imetric reaction was developed with 3,3′ ,5,5′ -tetramethylbenzidine (TMB) substrate solution and terminated 
with 2 N H2SO4. Then, absorbance at 450 nm (reference, 570 nm) was read by an automated microplate reader 
(Benchmark, Bio-RAD, Hercules, CA). The serum cytokine levels were determined by comparison with a stand-
ard curve obtained using recombinant human IL-2 and IL-6, respectively23.
Definitions.  The diagnosis of SLE was based on the revised classification criteria of the American College of 
Rheumatology in 1997 in two cohorts of SLE2. The classification is based on 11 criteria and the diagnosis of SLE 
was made if any 4 or more of the 11 criteria are present, serially or simultaneously, during any interval of obser-
vation. The 11 criteria are as follows: malar rash, discoid rash, photosensitivity, oral ulcers, nonerosive arthritis 
involving 2 or more peripheral joints, pleuritis or pericarditis, renal disorder (persistent proteinuria > 0.5 grams 
per day or > than 3+ if quantitation not performed or cellular casts–may be red cell, hemoglobin, granular, 
tubular, or mixed), neurologic disorder (seizures or psychosis), hematologic disorder (hemolytic anemia with 
reticulocytosis or leukopenia < 4,000/mm3 on ≥ 2 occasions or lymphopenia < 1,500/mm3 on ≥ 2 occasions or 
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thrombocytopenia < 100,000/mm3 in the absence of offending drugs), immunologic disorder (anti-ds DNA in 
abnormal titer or anti-Sm or positive finding of antiphospholipid antibodies) and positive antinuclear antibody2.
Hyponatremia was defined as serum sodium level ≤ 135 mEq/L. SLE activity was considered serologically 
as the increased titers of anti-ds DNA antibodies and decreased complement levels, such as C3 < 90 mg/dL and 
C4 < 10 mg/dL and SLEDAI was also measured1.
Statistical methods. Statistical analyses were performed, using the SPSS for Windows (SPSS Inc., Chicago, 
Illinois, USA) and MedCalc version 15.8 (MedCalc Software, Ostend, Belgium). The independent t-test and 
Mann-Whitney U test was used for continuous variables and expressed as mean ± standard deviation. Fisher’s 
exact test was used to analyze categorical variables. Correlation analysis was also carried out to determine the 
relationship between two variables by Spearman or Pearson correlation. We also analyzed whether the changes 
(Δ : follow-up levels- initial levels) of serum sodium correlated with the changes (Δ ) of other parameters in a 
cohort of children with SLE. Multiple logistic regression analysis was used to find independent predictive factors 
for hyponatremia in lupus. To establish the predictive value of the parameters for predicting hyponatremia, ROC 
curves were plotted for laboratory tests. All differences were considered significant at a value of p < 0.05
This study design and the use of patients’ information stored in the hospital database were approved by the 
Institutional Review Board and the research ethics committee of Yonsei Severance Hospital and Ajou University 
Hospital. We were given exemption from getting informed consents by the two IRBs because the present study is 
a retrospective study and personal identifiers were completely removed and the data were analyzed anonymously. 
Our study was conducted according to the ethical standards laid down in the 1964 Declaration of Helsinki and 
its later amendments.
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